BCR/integrin interaction in CLL: a physiological remnant with clinical relevance.

Erika Tissino,Riccardo Bomben,Valter Gattei,Antonella Zucchetto

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 0|浏览9

暂无评分

摘要

CD49d, the alpha chain of the VLA-4 integrin, has a negative prognostic impact in CLL treated with the BTK-inhibitors ibrutinib and acalabrutinib. Despite BTK inhibition, VLA-4 remains inside-out activated via BCR, an activation dampened by PI3K-inhibitors. Evaluation of CD49d expression in patients starting BTK-inhibitor therapy may improve their prognostic stratification.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要